Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
GLP-1 receptor agonists have shown strong efficacy in promoting weight loss and improving glycemic control, making them a preferred choice for patients with obesity, type 2 diabetes, and cardiovascular risk factors
Furthermore, many studies rely on surrogate endpoints, such as oocyte maturation, fertilization rate, or oxidative stress biomarkers, rather than on clinically meaningful reproductive outcomes, such as the live birth rate
Clinical trials suggest retatrutide dosing will start low, with incremental increase every four weeks, similarly to drugs like Zepbound and Wegovy
The mechanism simply doesn't align
And it should, because safety data often matters more than efficacy data for individual treatment decisions
